Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5

Journal of Virology

Volumn 75, Issue 22, 2001, Pages 10906-10911

  Parker, C E ^a   Deterding, L J ^a   Hager Braun, C ^a   Binley, J M ^a   Schulke N ^a   Katinger, H ^a   Moore, J P ^a   Tomer, K B ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CHO CELLS; CRICETINAE; EPITOPE MAPPING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS;

EID: 0034755554     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.22.10906-10911.2001     Document Type: Article

References (61)

1. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
2. Human neutralizing monoclonal antibodies of the IgG?? subtype protect against mucosal simian-human immunodeficiency virus infection
3. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys
4. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
5. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
6. Human antibody responses to HIV-1 gly. coprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding
7. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
8. Generation of human monoclonal antibodies against HIV-1 proteins: Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
9. A vaccine for HIV type 1: The antibody perspective Proc
10. The antibody response in HIV-1 infection
11. Why do we not have an HIV vaccine and how can we make one?
12. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
13. A structure-based approach to a synthetic vaccine for HIV-1
14. HIV entry and its inhibition
15. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein
16. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-v3 monoclonal-antibody, 447-52D
17. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5: An anti-gp41 human monoclonal antibody
18. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1
19. HIV-1 membrane fusion; targets of opportunity
20. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41
21. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
22. + T-cell responses from chronically infected individuals
23. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
24. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody
25. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41
26. HIV vaccines: Where are we going?
27. Mass spectrometric characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A
28. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41 mediated virus entry
29. Progress in the development of an HIV-1 vaccine
30. Induction of high level of specific antibody response to the neutralizing epitope ELDK WA on HIV-1 gp41 by peptide-vaccine
31. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1
32. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein
33. A trimeric structural domain of the HIV-1 transmembrane domain
34. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
35. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
36. Cellular immune responses to HIV
37. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
38. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
39. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
40. Challenges and opportunities for development of an AIDS vaccine
41. Epitope mapping by a combination of epitope excision and MALDI-MS
42. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
43. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
44. A general strategy for epitope mapping by direct MALDI-TOF mass spectrometry using secondary antibodies and crosslinking
45. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
46. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1
47. Protein design of an HIV-1 entry inhibitor
48. The role of cellular immunity in protection against HIV infection
49. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity
50. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
51. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules
52. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
53. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4 immunoglobulin G
54. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
55. Atomic structure of the ectodomain from HIV-1 gp41
56. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion
57. Epitopevaccines: A new strategy to induce high levels of neutralizing antibodies against HIV-1
58. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1
59. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine
60. Epitope- vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody